The Future Directions of Psychedelics: A Conversation With Guy Goodwin, MD

BRAIN TRUST: CONVERSATIONS IN PSYCHOPHARMACOLOGY

-Series Editor Joseph F. Goldberg, MD

This video contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Undue reliance should not be placed on these statements and the full context sought from filings by the company to the SEC.

Joseph F. Goldberg, MD, in this installment of "Brain Trust: Conversations in Psychopharmacology," sits down with Guy Goodwin, MD, to discuss the potential of psychedelics in treating depression and other mental health conditions. Goodwin, who is the chief medical officer at Compass Pathways, highlights psilocybin's ability to induce profound experiences that can lead to long-term improvements in mood and anxiety.

"I got the opportunity to go full time into a new position with Compass Pathways to develop psilocybin. I'd been interested already, I'd advised a little bit on how to design the phase 2 clinical trial. At the time that I did that, I was a little pessimistic about whether there was really a future in this, because it looked quite hard to raise money and quite difficult to do the studies. There were a lot of things that seemed to me potentially difficult, but many of these obstacles have become overcome by the people at Compass. That was the beginning of a new life," Goodwin said of his research evolution in psilocybin.

LSD, the first psychedelic, discovered in 1943 by Albert Hofmann,¹ "was the stimulus to understanding serotonin metabolism and function, both in the brain and to a lesser extent, in the peripheral nervous system," shared Goodwin.

Together, Goldberg and Goodwin evaluate the challenges of developing psilocybin, including regulatory hurdles and the need for careful clinical settings.

Goodwin notes that psilocybin's effects are immediate and can be more effective than traditional treatments for some patients. They also touch on the potential for psilocybin to treat posttraumatic stress disorder (PTSD) and substance abuse, and the importance of understanding its pharmacodynamic properties and potential combinations with other drugs.

For example, in an open-label, small study of 22 patients with PTSD, Goodwin and investigators saw an approximate 80% remission rate in symptoms.² In the follow up interviews with patients, Goodwin found a few details very striking: "One is that patients can have the trauma recur—the actual index trauma can be something that recurs in the experience under the influence of psilocybin—and it seems to be something that is tolerated by the patient. They kind of find an indirect route to feeling better about the trauma."

As to future directions, Goodwin believes we should start carefully: "We're advocating for very careful use. We're advocating reimbursement so that access is fair and equitable. Our objective is not to get this widest possible use of the drugs; Our objective is to get the proper use of the drugs in the right patient population."

Dr Goldberg is a clinical professor of psychiatry at The Icahn School of Medicine at Mount Sinai in New York, NY and the immediate-past president of the American Society of Clinical Psychopharmacology.

Dr Goodwin is the chief medical officer at Compass Pathways, as well as the Emeritus Professor of Psychiatry and NIHR Emeritus Senior Investigator at the University of Oxford, UK.

References

1. Dyck E. LSD: a new treatment emerging from the past. CMAJ. 2015;187(14):1079-1080.

2. Compass Pathways announces investigational COMP360 psilocybin treatment was well-tolerated in phase 2 study of post-traumatic stress disorder. News release. December 19, 2023. Accessed December 4, 2025. https://www.globenewswire.com/news-release/2023/12/19/2798886/0/en/Compass-Pathways-announces-investigational-COMP360-psilocybin-treatment-was-well-tolerated-in-phase-2-study-of-post-traumatic-stress-disorder.html